{"protocolSection":{"identificationModule":{"nctId":"NCT02411448","orgStudyIdInfo":{"id":"15540"},"secondaryIdInfos":[{"id":"I4T-MC-JVCY","type":"OTHER","domain":"Eli Lilly and Company"},{"id":"2014-004824-22","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)","officialTitle":"A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer","acronym":"RELAY"},"statusModule":{"statusVerifiedDate":"2025-04","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-05-06","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2019-01-23","type":"ACTUAL"},"completionDateStruct":{"date":"2025-12","type":"ESTIMATED"},"studyFirstSubmitDate":"2015-04-03","studyFirstSubmitQcDate":"2015-04-03","studyFirstPostDateStruct":{"date":"2015-04-08","type":"ESTIMATED"},"resultsFirstSubmitDate":"2020-01-17","resultsFirstSubmitQcDate":"2020-02-18","resultsFirstPostDateStruct":{"date":"2020-03-04","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-04-17","lastUpdatePostDateStruct":{"date":"2025-04-20","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The main purpose of this study is to evaluate the efficacy and safety of ramucirumab in combination with erlotinib as compared to placebo in combination with erlotinib in previously untreated participants with stage IV non-small cell lung cancer (NSCLC) harboring an activating epidermal growth factor receptor (EGFR) mutation (Exon 19-Del and Exon 21 L858R). Safety and tolerability of ramucirumab in combination with erlotinib will be assessed in Part A before proceeding to Part B.\n\nThe purpose of Part C is to determine the efficacy and safety of ramucirumab in combination with gefitinib in previously untreated East Asian participants with EGFR mutation-positive metastatic NSCLC and of ramucirumab in combination with osimertinib in those participants whose disease progressed on ramucirumab and gefitinib and that have T790M - positive metastatic NSCLC."},"conditionsModule":{"conditions":["Metastatic Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":545,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Ramucirumab + Erlotinib","type":"EXPERIMENTAL","description":"Part A: 10 milligrams per kilogram (mg/kg) ramucirumab administered every 2 weeks intravenously (IV) in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met.\n\nPart B: 10 mg/kg ramucirumab administered every 2 weeks IV in combination with 150 mg erlotinib daily orally. Participants may continue to receive treatment until discontinuation criteria are met.","interventionNames":["Drug: Ramucirumab","Drug: Erlotinib"]},{"label":"Placebo + Erlotinib","type":"PLACEBO_COMPARATOR","description":"Part B: Placebo administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met.","interventionNames":["Drug: Placebo","Drug: Erlotinib"]},{"label":"Ramucirumab + Gefitinib or Osimertinib","type":"EXPERIMENTAL","description":"Part C: 10 mg/kg ramucirumab administered every 2 weeks intravenously (IV) + 250 mg Gefitinib or 80 mg Osimertinib daily orally.\n\n* Ramucirumab and gefitinib administered during period 1.\n* Ramucirumab and osimertinib administered during period 2.","interventionNames":["Drug: Ramucirumab","Drug: Gefitinib","Drug: Osimertinib"]}],"interventions":[{"type":"DRUG","name":"Ramucirumab","description":"Administered IV.","armGroupLabels":["Ramucirumab + Erlotinib","Ramucirumab + Gefitinib or Osimertinib"],"otherNames":["LY3009806"]},{"type":"DRUG","name":"Placebo","description":"Administered IV.","armGroupLabels":["Placebo + Erlotinib"]},{"type":"DRUG","name":"Erlotinib","description":"Administered orally.","armGroupLabels":["Placebo + Erlotinib","Ramucirumab + Erlotinib"]},{"type":"DRUG","name":"Gefitinib","description":"Administered orally.","armGroupLabels":["Ramucirumab + Gefitinib or Osimertinib"]},{"type":"DRUG","name":"Osimertinib","description":"Administered orally.","armGroupLabels":["Ramucirumab + Gefitinib or Osimertinib"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Part B: Progression Free Survival (PFS)","description":"PFS is defined as the time from the date of randomization to the date of radiographically documented progressive disease (PD) based on investigator assessment, or the date of death due to any cause, whichever is first assessed via Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.","timeFrame":"Randomization to Measured Progressive Disease or Death from Any Cause (Up To 37 Months)"},{"measure":"Number of Participants With Treatment-Emergent Adverse Events","description":"A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.","timeFrame":"Cycle 1 Day 1 through End of Study (Up To 3 Years)"}],"secondaryOutcomes":[{"measure":"Part B: Overall Survival (OS)","description":"OS was defined as the time from the date of randomization to the date of death from any cause. For each participant who was not known to have died as of the data-inclusion cutoff date for a particular analysis,OS was censored for that analysis at the date of last contact prior to the data-inclusion cutoff date (contacts considered in the determination of last contact date include adverse event (AE) date, lesion assessment date, visit date, and last known alive date).","timeFrame":"Randomization to Date of Death from Any Cause (Up To 37 Months)"},{"measure":"Part B: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])","description":"ORR was defined as the percentage of randomized participants achieving a best overall response of partial response (PR) or complete response (CR) assessed via Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR was defined as the disappearance of all lesions, pathological lymph node reduction in short axis to \\<10 mm, and normalization of tumor marker levels of non-target lesions. PR was at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.","timeFrame":"Randomization to Progressive Disease (Up To 37 Months)"},{"measure":"Part B: Percentage of Participants With CR, PR, or Stable Disease (SD) (Disease Control Rate [DCR])","description":"DCR was defined as the percentage of randomized participants achieving a best overall response of CR,PR, or stable disease(SD) assessed via Response Evaluation Criteria in Solid Tumors(RECIST) version 1.1. CR was defined as the disappearance of all lesions,pathological lymph node reduction in short axis to \\<10 mm, and normalization of tumor marker levels of non-target lesions.PR was at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters.SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease(PD) was at least a 20% increase in the sum of the diameters of target lesions,taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.The appearance of 1 or more new lesions is also considered progression.","timeFrame":"Randomization to Progressive Disease (Up To 37 Months)"},{"measure":"Part B: Duration of Response (DoR)","description":"DoR was defined as the date of first documented CR or PR (responder) to the date of progressive disease or the date of death due to any cause, whichever was earlier. If a responder was not known to have died or have progressive disease, then the participant was censored at the date of last evaluable tumor assessment.CR was defined as the disappearance of all lesions, pathological lymph node reduction in short axis to \\<10 mm, and normalization of tumor marker levels of non-target lesions. PR was at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.","timeFrame":"Date of Complete Response (CR) or Partial Response (PR) to Date of Objective Disease Progression or Death Due to Any Cause (Up To 37 Months)"},{"measure":"Part B: Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab","description":"Part B: Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab","timeFrame":"Cycle 2 Day 1: Predose; Cycle 4 Day 1: Predose; Cycle 7 Day 1: Predose; Cycle 14 Day 1"},{"measure":"Part B: Number of Participants With Anti-Ramucirumab Antibodies","description":"Part B: Number of Participants With Anti-Ramucirumab Antibodies.","timeFrame":"Cycle 1 Predose through Follow-up (Up To 37 Months)"},{"measure":"Part B: Best Change From Baseline on the Lung Cancer Symptom Scale (LCSS)","description":"The LCSS consisted of 9 items: 6 items focused on lung cancer symptoms \\[loss of appetite, fatigue, cough, dyspnea (shortness of breath), hemoptysis (blood in sputum), and pain\\] and 3 global items (symptom distress, interference with activity level, and global quality of life). Participant responses to each item were measured using visual analogue scales (VAS) with 100-millimeter (mm) lines. A higher score for any item represented a higher level of symptoms/problems. The LCSS total score was defined as the mean of all 9 items. Average symptom burden index (ASBI) was calculated as the mean of the six symptom-specific questions from the LCSS. Potential scores range from 0 (for best outcome) to 100 (for worst outcome).","timeFrame":"Baseline, End of Study (Up To 37 Months)"},{"measure":"Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score","description":"The EQ-5D-5L is a standardized instrument used to measure self-reported health status of the participants. It consists of 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). There are 5 response levels (no problems, slight problems, moderate problems, severe problems, and extreme problems/unable to), ranging from 1 to 5 (good to bad). Dimension responses were converted to an index score using UK weights. The index scores were anchored on full health (1.0) to dead (0) with negative values assigned to health states considered worse than death.","timeFrame":"Baseline, Cycle 10 (each cycle is 2 weeks)"},{"measure":"Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score","description":"The EQ-5D-5L is a standardized instrument used to measure self-reported health status of the participants. It consists of 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). There are 5 response levels (no problems, slight problems, moderate problems, severe problems, and extreme problems/unable to), ranging from 1 to 5 (good to bad). Dimension responses were converted to an index score using UK weights. The index scores were anchored on full health (1.0) to dead (0) with negative values assigned to health states considered worse than death.","timeFrame":"Baseline, Cycle 28 (each cycle is 2 weeks)"},{"measure":"Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score","description":"The EQ-5D-5L is a standardized instrument used to measure self-reported health status of the participants. It consists of 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). There are 5 response levels (no problems, slight problems, moderate problems, severe problems, and extreme problems/unable to), ranging from 1 to 5 (good to bad). Dimension responses were converted to an index score using UK weights. The index scores were anchored on full health (1.0) to dead (0) with negative values assigned to health states considered worse than death.","timeFrame":"Baseline, Cycle 40 (each cycle is 2 weeks)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Cytologically or histologically confirmed diagnosis of Stage IV NSCLC as defined by the American Joint Committee on Cancer Staging Criteria for Lung Cancer (AJCC 7th edition 2009).\n* Eligible for first-line treatment with erlotinib based on documented evidence of tumor harboring an activating EGFR mutation \\[exon 19 deletion or exon 21 (L858R) substitution mutation\\].\n* Mandatory provision of adequate archived stage IV NSCLC tissue samples or tissue samples other than stage IV NSCLC may be acceptable (optional for part C).\n* At least one measurable lesion.\n* Life expectancy of at least 3 months.\n\nExclusion Criteria:\n\n* Known T790M EGFR mutation (not applicable for Part C Period 2).\n* Known leptomeningeal carcinomatosis, uncontrolled/unstable spinal cord compression, or brain metastases.\n* Serious illness or medical condition.\n* Ongoing treatment with CYP3A4 inducers or strong inhibitors.\n* Ongoing therapy with nonsteroidal anti-inflammatory drugs for more than 2 months.\n* History of gross hemoptysis.\n* Significant bleeding disorders.\n* Radiologically documented evidence of major blood vessel invasion or encasement by cancer.\n* Radiographic evidence of intratumor cavitation.\n* History of gastrointestinal perforation within last 6 months.\n* History of bowel obstruction, inflammatory enteropathy or extensive intestinal resection.\n* History of any arterial thrombotic event within 6 months prior to enrollment.\n* The participant has any known significant ophthalmologic abnormalities of the surface of the eye.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"UCLA Hematology/Oncology - Santa Monica","city":"Los Angeles","state":"California","zip":"90404","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"St. Charles Health System","city":"Denver","state":"Colorado","zip":"80203","country":"United States","geoPoint":{"lat":39.73915,"lon":-104.9847}},{"facility":"The Gastroenterology Group, P.C.","city":"Honolulu","state":"Hawaii","zip":"96813","country":"United States","geoPoint":{"lat":21.30694,"lon":-157.85833}},{"facility":"Cancer Center of Kansas","city":"Wichita","state":"Kansas","zip":"67214","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"Queens Medical Associates","city":"Fresh Meadows","state":"New York","zip":"11366","country":"United States","geoPoint":{"lat":40.73482,"lon":-73.79347}},{"facility":"Levine Cancer Institute","city":"Charlotte","state":"North Carolina","zip":"28204","country":"United States","geoPoint":{"lat":35.22709,"lon":-80.84313}},{"facility":"AHN Allegheny General Hospital","city":"Pittsburgh","state":"Pennsylvania","zip":"15212","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"Cross Cancer Institute","city":"Edmonton","state":"Alberta","zip":"T6G 1Z2","country":"Canada","geoPoint":{"lat":53.55014,"lon":-113.46871}},{"facility":"Hôpital Arnaud de Villeneuve - CHU Montpellier","city":"Montpellier","state":"Hérault","zip":"34090","country":"France","geoPoint":{"lat":43.61093,"lon":3.87635}},{"facility":"Chu Grenoble Alpes","city":"La Tronche","state":"Isère","zip":"38700","country":"France","geoPoint":{"lat":45.20507,"lon":5.74629}},{"facility":"Hopital Claude Huriez - CHU de Lille","city":"Lille","state":"Nord","zip":"59037","country":"France","geoPoint":{"lat":50.63391,"lon":3.05512}},{"facility":"Centre Hospitalier Universitaire de Poitiers","city":"Poitiers","state":"Vienne","zip":"86021","country":"France","geoPoint":{"lat":46.58261,"lon":0.34348}},{"facility":"Hôpital Européen Georges Pompidou","city":"Paris","zip":"75015","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Robert-Bosch-Krankenhaus","city":"Gerlingen","state":"Baden-Wurttemberg","zip":"70839","country":"Germany","geoPoint":{"lat":48.79954,"lon":9.06316}},{"facility":"Thoraxklinik Heidelberg gGmbH","city":"Heidelberg","state":"Baden-Wurttemberg","zip":"69126","country":"Germany","geoPoint":{"lat":49.40768,"lon":8.69079}},{"facility":"Klinikum Köln-Merheim","city":"Cologne","state":"North Rhine-Westphalia","zip":"51109","country":"Germany","geoPoint":{"lat":50.93333,"lon":6.95}},{"facility":"Klinikum Chemnitz GmbH","city":"Chemnitz","state":"Saxony","zip":"09113","country":"Germany","geoPoint":{"lat":50.8357,"lon":12.92922}},{"facility":"Städtisches Krankenhaus Martha-Maria Halle-Dölau gGmbH","city":"Halle","state":"Saxony-Anhalt","zip":"06120","country":"Germany","geoPoint":{"lat":51.48158,"lon":11.97947}},{"facility":"LungenClinic Grosshansdorf","city":"Großhansdorf","state":"Schleswig-Holstein","zip":"22927","country":"Germany","geoPoint":{"lat":53.66528,"lon":10.28552}},{"facility":"Helios Klinikum Emil von Behring Berlin-Zehlendorf","city":"Berlin","zip":"14165","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Sotiria Thoracic Diseases Hospital of Athens","city":"Athens","state":"Attikí","zip":"11527","country":"Greece","geoPoint":{"lat":37.98376,"lon":23.72784}},{"facility":"Queen Mary Hospital","city":"Hong Kong","country":"Hong Kong","geoPoint":{"lat":22.27832,"lon":114.17469}},{"facility":"Queen Elizabeth Hospital","city":"Yau Ma Tei","zip":"999077","country":"Hong Kong","geoPoint":{"lat":22.3138,"lon":114.16857}},{"facility":"Instituto Tumori Giovanni Paolo II","city":"Bari","state":"Apulia","zip":"70124","country":"Italy","geoPoint":{"lat":41.12066,"lon":16.86982}},{"facility":"Cro-Irccs","city":"Aviano","state":"Friuli Venezia Giulia","zip":"33081","country":"Italy","geoPoint":{"lat":46.07056,"lon":12.59472}},{"facility":"Azienda Sanitaria Ospedaliera S Luigi Gonzaga","city":"Orbassano","state":"Torino","zip":"10043","country":"Italy","geoPoint":{"lat":45.00547,"lon":7.53813}},{"facility":"IRCCS - AOU di Bologna","city":"Bologna","zip":"40138","country":"Italy","geoPoint":{"lat":44.49381,"lon":11.33875}},{"facility":"Ospedale San Raffaele","city":"Milan","zip":"20132","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Istituto Oncologico Veneto IRCCS","city":"Padua","zip":"35128","country":"Italy","geoPoint":{"lat":45.40797,"lon":11.88586}},{"facility":"Aichi Cancer Center Hospital","city":"Nagoya","state":"Aichi-ken","zip":"464-8681","country":"Japan","geoPoint":{"lat":35.18147,"lon":136.90641}},{"facility":"National Cancer Center Hospital East","city":"Kashiwa","state":"Chiba","zip":"277 8577","country":"Japan","geoPoint":{"lat":35.86224,"lon":139.97732}},{"facility":"Ehime University Hospital","city":"Tōon","state":"Ehime","zip":"791-0295","country":"Japan","geoPoint":{"lat":33.79427,"lon":132.89011}},{"facility":"Kurume University Hospital","city":"Kurume","state":"Fukuoka","zip":"830-0011","country":"Japan","geoPoint":{"lat":33.31667,"lon":130.51667}},{"facility":"National Hospital Organization Asahikawa Medical Center","city":"Asahikawa","state":"Hokkaido","zip":"070-8644","country":"Japan","geoPoint":{"lat":43.77063,"lon":142.36489}},{"facility":"Hyogo Cancer Center","city":"Akashi","state":"Hyōgo","zip":"673-8558","country":"Japan","geoPoint":{"lat":34.65524,"lon":135.00687}},{"facility":"Hyogo Prefectual Amagasaki General Medical Center","city":"Amagashiki","state":"Hyōgo","zip":"660-8550","country":"Japan"},{"facility":"Himeji Medical Center","city":"Himeji","state":"Hyōgo","zip":"670-8520","country":"Japan","geoPoint":{"lat":34.81667,"lon":134.7}},{"facility":"Foundation for Biomedical Research and innovation","city":"Kobe","state":"Hyōgo","zip":"650-0047","country":"Japan","geoPoint":{"lat":34.6913,"lon":135.183}},{"facility":"Kobe City Medical Center General Hospital","city":"Kobe","state":"Hyōgo","zip":"650-0047","country":"Japan","geoPoint":{"lat":34.6913,"lon":135.183}},{"facility":"Kanazawa University Hospital","city":"Kanazawa","state":"Ishikawa-ken","zip":"920-8641","country":"Japan","geoPoint":{"lat":36.6,"lon":136.61667}},{"facility":"Kanagawa Cardiovascular and Respiratory Center","city":"Yokohama","state":"Kanagawa","zip":"236-0051","country":"Japan","geoPoint":{"lat":35.43333,"lon":139.65}},{"facility":"Kanagawa Cancer Center","city":"Yokohama","state":"Kanagawa","zip":"241-8515","country":"Japan","geoPoint":{"lat":35.43333,"lon":139.65}},{"facility":"Sendai Kousei Hospital","city":"Sendai","state":"Miyagi","zip":"9800873","country":"Japan","geoPoint":{"lat":38.26667,"lon":140.86667}},{"facility":"Niigata Cancer Center Hospital","city":"Niigata","state":"Niigata","zip":"951-8566","country":"Japan","geoPoint":{"lat":37.92259,"lon":139.04125}},{"facility":"Osaka Habikino Medical Center","city":"Habikino","state":"Osaka","zip":"583-8588","country":"Japan","geoPoint":{"lat":34.55276,"lon":135.59097}},{"facility":"Kansai Medical University Hospital","city":"Hirakata","state":"Osaka","zip":"573-1191","country":"Japan","geoPoint":{"lat":34.81352,"lon":135.64914}},{"facility":"Kishiwada City Hospital","city":"Kishiwada","state":"Osaka","zip":"596-8501","country":"Japan","geoPoint":{"lat":34.46667,"lon":135.36667}},{"facility":"Kindai University Hospital- Osakasayama Campus","city":"Ōsaka-sayama","state":"Osaka","zip":"589-8511","country":"Japan","geoPoint":{"lat":34.49524,"lon":135.55069}},{"facility":"National Hospital Organization Kinki-Chuo Chest Medical Center","city":"Sakai","state":"Osaka","zip":"5918555","country":"Japan","geoPoint":{"lat":34.58216,"lon":135.46653}},{"facility":"Saitama Prefectural Cancer Center","city":"Ina-machi","state":"Saitama","zip":"362-0806","country":"Japan"},{"facility":"Shizuoka Cancer Center","city":"Nakatogari","state":"Shizuoka","zip":"411-8777","country":"Japan","geoPoint":{"lat":35.13526,"lon":138.9028}},{"facility":"Tokyo Met Cancer & Infectious Diseases Center Komagome Hp","city":"Bunkyo-ku","state":"Tokyo","zip":"113-8677","country":"Japan"},{"facility":"National Cancer Center Hospital","city":"Chuo-Ku","state":"Tokyo","zip":"104-0045","country":"Japan"},{"facility":"Japanese Foundation for Cancer Research","city":"Koto","state":"Tokyo","zip":"135-8550","country":"Japan"},{"facility":"National Hospital Organization Yamaguchi Ube Medical Center","city":"Ube","state":"Yamaguchi","zip":"755-0241","country":"Japan","geoPoint":{"lat":33.94306,"lon":131.25111}},{"facility":"Chiba University Hospital","city":"Chiba","zip":"260-8677","country":"Japan","geoPoint":{"lat":35.6,"lon":140.11667}},{"facility":"National Hospital Organization Kyushu Medical Center","city":"Fukuoka","zip":"810-8563","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"National Hospital Organization Kyushu Cancer Center","city":"Fukuoka","zip":"811-1395","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"Kyushu University Hospital","city":"Fukuoka","zip":"812-8582","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"Kyoto University Hospital","city":"Kyoto","zip":"606-8507","country":"Japan","geoPoint":{"lat":35.02107,"lon":135.75385}},{"facility":"Nagasaki University Hospital","city":"Nagasaki","zip":"852-8501","country":"Japan","geoPoint":{"lat":32.75,"lon":129.88333}},{"facility":"Niigata University Medical & Dental Hospital","city":"Niigata","zip":"951-8520","country":"Japan","geoPoint":{"lat":37.92259,"lon":139.04125}},{"facility":"Okayama University Hospital","city":"Okayama","zip":"700-8558","country":"Japan","geoPoint":{"lat":34.65,"lon":133.93333}},{"facility":"Osaka City General Hospital","city":"Osaka","zip":"534-0021","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"Osaka Medical Center for Cancer and Cardiovascular Diseases","city":"Osaka","zip":"537-8511","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"Osaka City University Hospital","city":"Osaka","zip":"545-8586","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"St. Lukes International Hospital","city":"Tokyo","zip":"104-8560","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"Juntendo University Hospital","city":"Tokyo","zip":"113-8431","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"Nippon Medical School Hospital","city":"Tokyo","zip":"113-8603","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"Wakayama MedicaL University Hospital","city":"Wakayama","zip":"641-0012","country":"Japan","geoPoint":{"lat":34.23333,"lon":135.16667}},{"facility":"Institutul Oncologic","city":"Bucharest","state":"București","zip":"022328","country":"Romania","geoPoint":{"lat":44.43225,"lon":26.10626}},{"facility":"S.C. MedisProf SRL","city":"Cluj-Napoca","state":"Cluj","zip":"400058","country":"Romania","geoPoint":{"lat":46.76667,"lon":23.6}},{"facility":"Chungbuk National University Hospital","city":"Cheongju-si","state":"Chungcheongbuk-do [Chungbuk]","zip":"28644","country":"South Korea","geoPoint":{"lat":36.63722,"lon":127.48972}},{"facility":"Seoul National University Bundang Hospital","city":"Seongnam","state":"Kyǒnggi-do","zip":"10408","country":"South Korea","geoPoint":{"lat":35.54127,"lon":127.39683}},{"facility":"The Catholic University Of Korea St. Vincent's Hospital","city":"Suwon","state":"Kyǒnggi-do","zip":"16247","country":"South Korea","geoPoint":{"lat":37.29111,"lon":127.00889}},{"facility":"Ajou University Hospital","city":"Suwon","state":"Kyǒnggi-do","zip":"16499","country":"South Korea","geoPoint":{"lat":37.29111,"lon":127.00889}},{"facility":"Gyeongsang National University Hospital","city":"Jinju","state":"Kyǒngsangnam-do","zip":"52727","country":"South Korea","geoPoint":{"lat":35.19278,"lon":128.08472}},{"facility":"Asan Medical Center","city":"Seoul","state":"Seoul-teukbyeolsi [Seoul]","zip":"05505","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Samsung Medical Center","city":"Seoul","state":"Seoul-teukbyeolsi [Seoul]","zip":"06351","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"The Catholic Univ. of Korea Seoul St. Mary's Hospital","city":"Seoul","state":"Seoul-teukbyeolsi [Seoul]","zip":"06591","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Korea University Guro Hospital","city":"Seoul","state":"Seoul-teukbyeolsi [Seoul]","zip":"08308","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Ulsan University Hospital","city":"Ulsan","state":"Ulsan-Kwangyǒkshi","zip":"44033","country":"South Korea","geoPoint":{"lat":35.53722,"lon":129.31667}},{"facility":"Hospital Universitari Vall d'Hebron","city":"Barcelona","state":"Barcelona [Barcelona]","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Instituto Catalan de Oncologia - Hospital Duran i Reynals","city":"Hospitalet","state":"Barcelona [Barcelona]","zip":"08908","country":"Spain"},{"facility":"Hospital Son Llatzer","city":"Palma","state":"Illes Balears [Islas Baleares]","zip":"07198","country":"Spain","geoPoint":{"lat":39.56939,"lon":2.65024}},{"facility":"Hospital Universitario Quironsalud Madrid","city":"Pozuelo de Alarcón","state":"Madrid","zip":"28223","country":"Spain","geoPoint":{"lat":40.43293,"lon":-3.81338}},{"facility":"Hospital Universitario 12 de Octubre","city":"Madrid","state":"Madrid, Comunidad de","zip":"28041","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Clinica Universitaria De Navarra","city":"Pamplona","state":"Navarre","zip":"31008","country":"Spain","geoPoint":{"lat":42.81687,"lon":-1.64323}},{"facility":"Hospital Universitario Virgen del Rocio","city":"Seville","zip":"41013","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Hospital Universitario Virgen de Valme","city":"Seville","zip":"41014","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Hospital Universitari i Politecnic La Fe","city":"Valencia","zip":"46026","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Chang Gung Memorial Hospital at Kaohsiung","city":"Kaohsiung Niao Sung Dist","state":"Kaohsiung","zip":"83301","country":"Taiwan"},{"facility":"E-DA Hospital","city":"Kaohsiung City","zip":"82445","country":"Taiwan","geoPoint":{"lat":22.61626,"lon":120.31333}},{"facility":"China Medical University Hospital","city":"Taichung","zip":"40447","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"facility":"Taichung Veterans General Hospital","city":"Taichung","zip":"40705","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"facility":"National Cheng-Kung University Hospital","city":"Tainan","zip":"704","country":"Taiwan","geoPoint":{"lat":22.99083,"lon":120.21333}},{"facility":"National Taiwan University Hospital","city":"Taipei","zip":"10002","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"MacKay Memorial Hospital","city":"Taipei","zip":"10449","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Taipei Veterans General Hospital","city":"Taipei","zip":"11217","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Ege Universitesi Hastanesi","city":"Bornova","state":"İzmir","zip":"35100","country":"Turkey (Türkiye)","geoPoint":{"lat":38.47921,"lon":27.2399}},{"facility":"Baskent University Dr. Turgut Noyan Research and Training Center","city":"Adana","zip":"1250","country":"Turkey (Türkiye)","geoPoint":{"lat":36.98615,"lon":35.32531}},{"facility":"Trakya University","city":"Edirne","zip":"22030","country":"Turkey (Türkiye)","geoPoint":{"lat":41.67719,"lon":26.55597}},{"facility":"İnönü Üniversitesi Turgut Özal Tıp Merkezi Eğitim ve Araştırma Hastanesi","city":"Malatya","zip":"44280","country":"Turkey (Türkiye)","geoPoint":{"lat":38.35018,"lon":38.31667}},{"facility":"Royal Marsden Hospital (Chelsea)","city":"London","state":"Kensington and Chelsea","zip":"SW3 6JJ","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Charing Cross Hospital","city":"Chelsea","state":"London","zip":"W6 8RF","country":"United Kingdom","geoPoint":{"lat":51.48755,"lon":-0.16936}},{"facility":"City Hospital, Nottingham University Hospitals","city":"Nottingham","state":"Nottinghamshire","zip":"NG5 1PB","country":"United Kingdom","geoPoint":{"lat":52.9536,"lon":-1.15047}}]},"referencesModule":{"references":[{"pmid":"40995949","type":"DERIVED","citation":"Nishino K, Seto T, Nishio M, Nishio K, Kasahara K, Satouchi M, Yoh K, Hayashi H, Enatsu S, Matsui T, Varughese SC, Visseren-Grul C, Nakagawa K. RELAY: safety and efficacy of ramucirumab plus erlotinib in elderly Japanese patients with metastatic EGFR-mutated NSCLC. Future Oncol. 2025 Oct;21(24):3197-3206. doi: 10.1080/14796694.2025.2560225. Epub 2025 Sep 25."},{"pmid":"40458541","type":"DERIVED","citation":"Nishio M, Seto T, Reck M, Garon EB, Nishio K, Kasahara K, Nishino K, Satouchi M, Yoh K, Hayashi H, Sakai K, Enatsu S, Frimodt-Moller B, Matsui T, Varughese SC, Carlsen M, Visseren-Grul C, Nakagawa K. Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset. JTO Clin Res Rep. 2025 Feb 28;6(6):100819. doi: 10.1016/j.jtocrr.2025.100819. eCollection 2025 Jun."},{"pmid":"39622410","type":"DERIVED","citation":"Nakagawa K, Garon EB, Seto T, Nishio M, Aix SP, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Nishino K, Yoh K, Shih JY, Chik JYK, Moro-Sibilot D, Puri T, Chacko Varughese S, Frimodt-Moller B, Visseren-Grul C, Reck M. RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC. J Thorac Oncol. 2025 Apr;20(4):487-499. doi: 10.1016/j.jtho.2024.11.032. Epub 2024 Nov 30."},{"pmid":"37691865","type":"DERIVED","citation":"Nishio K, Sakai K, Nishio M, Seto T, Visseren-Grul C, Carlsen M, Matsui T, Enatsu S, Nakagawa K. Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized study). Transl Lung Cancer Res. 2023 Aug 30;12(8):1702-1716. doi: 10.21037/tlcr-22-736. Epub 2023 Aug 10."},{"pmid":"37390764","type":"DERIVED","citation":"Garon EB, Reck M, Nishio K, Heymach JV, Nishio M, Novello S, Paz-Ares L, Popat S, Aix SP, Graham H, Butts BD, Visseren-Grul C, Nakagawa K; RELAY study investigators. Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results. ESMO Open. 2023 Aug;8(4):101580. doi: 10.1016/j.esmoop.2023.101580. Epub 2023 Jun 28."},{"pmid":"37329423","type":"DERIVED","citation":"Chiu CH, Lin MC, Wei YF, Chang GC, Su WC, Hsia TC, Su J, Wang AK, Jen MH, Puri T, Shih JY. Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study. Target Oncol. 2023 Jul;18(4):505-515. doi: 10.1007/s11523-023-00975-5. Epub 2023 Jun 17."},{"pmid":"35841410","type":"DERIVED","citation":"Nakagawa K, Garon EB, Gao L, Callies S, Zimmermann A, Walgren R, Visseren-Grul C, Reck M. RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationship. Cancer Chemother Pharmacol. 2022 Aug;90(2):137-148. doi: 10.1007/s00280-022-04447-x. Epub 2022 Jul 16."},{"pmid":"35369607","type":"DERIVED","citation":"Nishio M, Nishio K, Reck M, Garon EB, Imamura F, Kawaguchi T, Yamaguchi H, Ikeda S, Hirano K, Visseren-Grul C, Ceccarelli M, Wijayawardana SR, Zimmermann A, Matsui T, Enatsu S, Nakagawa K. RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC. JTO Clin Res Rep. 2022 Feb 26;3(4):100303. doi: 10.1016/j.jtocrr.2022.100303. eCollection 2022 Apr."},{"pmid":"34928484","type":"DERIVED","citation":"Nadal E, Horinouchi H, Shih JY, Nakagawa K, Reck M, Garon EB, Wei YF, Kollmeier J, Frimodt-Moller B, Barrett E, Lipkovich O, Visseren-Grul C, Novello S. RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability. Drug Saf. 2022 Jan;45(1):45-64. doi: 10.1007/s40264-021-01127-2. Epub 2021 Dec 20."},{"pmid":"34795131","type":"DERIVED","citation":"Mitani S, Chen Y, Inoue K, Mori J, Gao L, Long A, Wakabayashi S. Clinical Impact of a Shortened Infusion Duration of Ramucirumab in Japanese Patients -A Model-Based Approach. Gan To Kagaku Ryoho. 2021 Nov;48(11):1381-1387."},{"pmid":"31591063","type":"DERIVED","citation":"Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M; RELAY Study Investigators. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Dec;20(12):1655-1669. doi: 10.1016/S1470-2045(19)30634-5. Epub 2019 Oct 4."},{"pmid":"29317191","type":"DERIVED","citation":"Reck M, Garon EB, Paz-Ares L, Ponce S, Jaime JC, Juan O, Nadal E, Kiura K, Widau RC, He S, Dalal R, Lee P, Nakagawa K. Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results. Clin Lung Cancer. 2018 May;19(3):213-220.e4. doi: 10.1016/j.cllc.2017.11.003. Epub 2017 Nov 21."},{"pmid":"27894601","type":"DERIVED","citation":"Garon EB, Reck M, Paz-Ares L, Ponce S, Jaime JC, Juan O, Nadal E, Lee P, Dalal R, Liu J, He S, Treat J, Nakagawa K. Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017 Jan;18(1):96-99. doi: 10.1016/j.cllc.2016.05.023. Epub 2016 Jun 8."}],"seeAlsoLinks":[{"label":"A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Participants With EGFR Mutation-Positive Metastatic NSCLC","url":"https://trials.lillytrialguide.com/en-US/trial/3pxvd64nCo8AmAgMMu6iSo"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.","infoTypes":["STUDY_PROTOCOL","SAP","CSR"],"timeFrame":"Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.","accessCriteria":"A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.","url":"https://vivli.org/"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"This study consists of 3 parts:\n\n* Part A: Open-label.\n* Part B: Randomized, double-blind and placebo-controlled.\n* Part C: Open-label.\n\nPart C data will be reported after study completion.","groups":[{"id":"FG000","title":"Part A: Ramucirumab + Erlotinib","description":"Part A: 10 milligrams per kilogram (mg/kg) ramucirumab administered every 2 weeks intravenously (IV) in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met."},{"id":"FG001","title":"Part B: Ramucirumab+ Erlotinib","description":"Part B: 10 mg/kg ramucirumab administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met."},{"id":"FG002","title":"Part B: Placebo+ Erlotinib","description":"Part B: Placebo administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"224"},{"groupId":"FG002","numSubjects":"225"}]},{"type":"Received at Least One Dose of Study Drug","achievements":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"221"},{"groupId":"FG002","numSubjects":"225"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"141"},{"groupId":"FG002","numSubjects":"173"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"83"},{"groupId":"FG002","numSubjects":"52"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"14"},{"groupId":"FG002","numSubjects":"9"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Did not receive study treatment","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Alive on study treatment","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"64"},{"groupId":"FG002","numSubjects":"43"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All enrolled participants. Part C data will be reported after study completion.","groups":[{"id":"BG000","title":"Part A: Ramucirumab + Erlotinib","description":"Part A: 10 milligrams per kilogram (mg/kg) ramucirumab administered every 2 weeks intravenously (IV) in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met."},{"id":"BG001","title":"Part B: Ramucirumab+ Erlotinib","description":"Part B: 10 mg/kg ramucirumab administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met."},{"id":"BG002","title":"Part B: Placebo+ Erlotinib","description":"Part B: Placebo administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"224"},{"groupId":"BG002","value":"225"},{"groupId":"BG003","value":"463"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"title":"Part A","categories":[{"measurements":[{"groupId":"BG000","value":"67.6","spread":"13.2"},{"groupId":"BG001","value":"NA","spread":"NA","comment":"Row represents Part A data only."},{"groupId":"BG002","value":"NA","spread":"NA","comment":"Row represents Part A data only."},{"groupId":"BG003","value":"67.6","spread":"13"}]}]},{"title":"Part B","categories":[{"measurements":[{"groupId":"BG000","value":"NA","spread":"NA","comment":"Row represents Part B data only."},{"groupId":"BG001","value":"63.7","spread":"10.2"},{"groupId":"BG002","value":"62.9","spread":"10.6"},{"groupId":"BG003","value":"63.3","spread":"10.4"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"141"},{"groupId":"BG002","value":"142"},{"groupId":"BG003","value":"294"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"83"},{"groupId":"BG002","value":"83"},{"groupId":"BG003","value":"169"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"23"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"150"},{"groupId":"BG002","value":"160"},{"groupId":"BG003","value":"311"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"61"},{"groupId":"BG002","value":"55"},{"groupId":"BG003","value":"129"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"172"},{"groupId":"BG002","value":"174"},{"groupId":"BG003","value":"353"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"48"},{"groupId":"BG003","value":"107"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"Romania","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"}]}]},{"title":"Hong Kong","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"15"}]}]},{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"9"}]}]},{"title":"Japan","categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"106"},{"groupId":"BG002","value":"105"},{"groupId":"BG003","value":"218"}]}]},{"title":"United Kingdom","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"7"}]}]},{"title":"Spain","categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"19"},{"groupId":"BG003","value":"49"}]}]},{"title":"Canada","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"2"}]}]},{"title":"South Korea","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"29"},{"groupId":"BG003","value":"54"}]}]},{"title":"Turkey","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"7"}]}]},{"title":"Taiwan","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"30"},{"groupId":"BG003","value":"56"}]}]},{"title":"Italy","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"20"}]}]},{"title":"France","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"11"}]}]},{"title":"Germany","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"13"}]}]}]},{"title":"Geographic Region","description":"\\* Geographic region \"Other\" includes Canada, France, Germany, Italy, Romania, Spain, Turkey, US, UK.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"East Asia","categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"166"},{"groupId":"BG002","value":"170"},{"groupId":"BG003","value":"343"}]}]},{"title":"Other*","categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"58"},{"groupId":"BG002","value":"55"},{"groupId":"BG003","value":"120"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Part B: Progression Free Survival (PFS)","description":"PFS is defined as the time from the date of randomization to the date of radiographically documented progressive disease (PD) based on investigator assessment, or the date of death due to any cause, whichever is first assessed via Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.","populationDescription":"Part B: All randomized participants grouped according to their assigned treatment at randomization. Censored participants were: Part B: Ramucirumab+ Erlotinib= 102 and Part B: Placebo+ Erlotinib= 67. Per protocol, Part A did not evaluate efficacy.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Randomization to Measured Progressive Disease or Death from Any Cause (Up To 37 Months)","groups":[{"id":"OG000","title":"Part B: Ramucirumab+ Erlotinib","description":"Part B: 10 mg/kg ramucirumab administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG001","title":"Part B: Placebo+ Erlotinib","description":"Part B: Placebo administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"225"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.4","lowerLimit":"15.4","upperLimit":"21.6"},{"groupId":"OG001","value":"12.4","lowerLimit":"11.0","upperLimit":"13.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"<0.0001","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.591","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.461","ciUpperLimit":"0.760"}]},{"type":"PRIMARY","title":"Number of Participants With Treatment-Emergent Adverse Events","description":"A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.","populationDescription":"All randomized participants who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"timeFrame":"Cycle 1 Day 1 through End of Study (Up To 3 Years)","groups":[{"id":"OG000","title":"Part A: Ramucirumab + Erlotinib","description":"Part A: 10 milligrams per kilogram (mg/kg) ramucirumab administered every 2 weeks intravenously (IV) in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG001","title":"Part B: Ramucirumab + Erlotinib","description":"Part B: 10 mg/kg ramucirumab administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG002","title":"Part B: Placebo + Erlotinib","description":"Part B: Placebo administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"221"},{"groupId":"OG002","value":"225"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"221"},{"groupId":"OG002","value":"225"}]}]}]},{"type":"SECONDARY","title":"Part B: Overall Survival (OS)","description":"OS was defined as the time from the date of randomization to the date of death from any cause. For each participant who was not known to have died as of the data-inclusion cutoff date for a particular analysis,OS was censored for that analysis at the date of last contact prior to the data-inclusion cutoff date (contacts considered in the determination of last contact date include adverse event (AE) date, lesion assessment date, visit date, and last known alive date).","populationDescription":"Part B: All randomized participants grouped according to their assigned treatment at randomization. Censored participants were: Part B: Ramucirumab+ Erlotinib= 187 and Part B: Placebo+ Erlotinib= 183. Per protocol, Part A did not evaluate efficacy.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization to Date of Death from Any Cause (Up To 37 Months)","groups":[{"id":"OG000","title":"Part B: Ramucirumab+ Erlotinib","description":"Part B: 10 mg/kg ramucirumab administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG001","title":"Part B: Placebo+ Erlotinib","description":"Part B: Placebo administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"225"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"There were not enough events/deaths to compute a median or 95% confidence interval."},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"There were not enough events/deaths to compute a median or 95% confidence interval."}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.4209","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.832","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.532","ciUpperLimit":"1.303"}]},{"type":"SECONDARY","title":"Part B: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])","description":"ORR was defined as the percentage of randomized participants achieving a best overall response of partial response (PR) or complete response (CR) assessed via Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR was defined as the disappearance of all lesions, pathological lymph node reduction in short axis to \\<10 mm, and normalization of tumor marker levels of non-target lesions. PR was at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.","populationDescription":"Part B: All randomized participants grouped according to their assigned treatment at randomization. Per protocol, Part A did not evaluate efficacy.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Randomization to Progressive Disease (Up To 37 Months)","groups":[{"id":"OG000","title":"Part B: Ramucirumab+ Erlotinib","description":"Part B: 10 mg/kg ramucirumab administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG001","title":"Part B: Placebo+ Erlotinib","description":"Part B: Placebo administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"225"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.3","lowerLimit":"70.8","upperLimit":"81.9"},{"groupId":"OG001","value":"74.7","lowerLimit":"69.0","upperLimit":"80.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.7413","statisticalMethod":"Cochran-Mantel-Haenszel"}]},{"type":"SECONDARY","title":"Part B: Percentage of Participants With CR, PR, or Stable Disease (SD) (Disease Control Rate [DCR])","description":"DCR was defined as the percentage of randomized participants achieving a best overall response of CR,PR, or stable disease(SD) assessed via Response Evaluation Criteria in Solid Tumors(RECIST) version 1.1. CR was defined as the disappearance of all lesions,pathological lymph node reduction in short axis to \\<10 mm, and normalization of tumor marker levels of non-target lesions.PR was at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters.SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease(PD) was at least a 20% increase in the sum of the diameters of target lesions,taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.The appearance of 1 or more new lesions is also considered progression.","populationDescription":"Part B: All randomized participants grouped according to their assigned treatment at randomization. Per protocol, Part A did not evaluate efficacy.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Randomization to Progressive Disease (Up To 37 Months)","groups":[{"id":"OG000","title":"Part B: Ramucirumab+ Erlotinib","description":"Part B: 10 mg/kg ramucirumab administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG001","title":"Part B: Placebo+ Erlotinib","description":"Part B: Placebo administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"225"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.1","lowerLimit":"92.3","upperLimit":"97.9"},{"groupId":"OG001","value":"95.6","lowerLimit":"92.9","upperLimit":"98.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"1.0000","statisticalMethod":"Cochran-Mantel-Haenszel"}]},{"type":"SECONDARY","title":"Part B: Duration of Response (DoR)","description":"DoR was defined as the date of first documented CR or PR (responder) to the date of progressive disease or the date of death due to any cause, whichever was earlier. If a responder was not known to have died or have progressive disease, then the participant was censored at the date of last evaluable tumor assessment.CR was defined as the disappearance of all lesions, pathological lymph node reduction in short axis to \\<10 mm, and normalization of tumor marker levels of non-target lesions. PR was at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression.","populationDescription":"Part B: All randomized participants grouped according to their assigned treatment at randomization that had a response (CR or PR). Per protocol, Part A did not evaluate efficacy.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Date of Complete Response (CR) or Partial Response (PR) to Date of Objective Disease Progression or Death Due to Any Cause (Up To 37 Months)","groups":[{"id":"OG000","title":"Part B: Ramucirumab+ Erlotinib","description":"Part B: 10 mg/kg ramucirumab administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG001","title":"Part B: Placebo+ Erlotinib","description":"Part B: Placebo administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"168"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.0","lowerLimit":"13.9","upperLimit":"19.8"},{"groupId":"OG001","value":"11.1","lowerLimit":"9.7","upperLimit":"12.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.0003","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.619","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.477","ciUpperLimit":"0.805"}]},{"type":"SECONDARY","title":"Part B: Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab","description":"Part B: Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab","populationDescription":"Part B participants who received at least one dose of Ramucirumab+ Erlotinib who had evaluable PK data. Per protocol, Part A did not evaluate PK.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"microgram per milliliter (µg/mL)","timeFrame":"Cycle 2 Day 1: Predose; Cycle 4 Day 1: Predose; Cycle 7 Day 1: Predose; Cycle 14 Day 1","groups":[{"id":"OG000","title":"Part B: Ramucirumab+ Erlotinib","description":"Part B: 10 mg/kg ramucirumab every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"}]}],"classes":[{"title":"Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"39.6","spread":"32"}]}]},{"title":"Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"145"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"68.5","spread":"37"}]}]},{"title":"Cycle 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"110"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"85.7","spread":"32"}]}]},{"title":"Cycle 14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99.4","spread":"31"}]}]}]},{"type":"SECONDARY","title":"Part B: Number of Participants With Anti-Ramucirumab Antibodies","description":"Part B: Number of Participants With Anti-Ramucirumab Antibodies.","populationDescription":"All participants who received at least one dose of study drug. Per protocol, Part A did not evaluate Anti-Ramucirumab Antibodies .","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"timeFrame":"Cycle 1 Predose through Follow-up (Up To 37 Months)","groups":[{"id":"OG000","title":"Part B: Ramucirumab+ Erlotinib","description":"Part B: 10 mg/kg ramucirumab administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG001","title":"Part B: Placebo+ Erlotinib","description":"Part B: Placebo administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"221"},{"groupId":"OG001","value":"225"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"18"}]}]}]},{"type":"SECONDARY","title":"Part B: Best Change From Baseline on the Lung Cancer Symptom Scale (LCSS)","description":"The LCSS consisted of 9 items: 6 items focused on lung cancer symptoms \\[loss of appetite, fatigue, cough, dyspnea (shortness of breath), hemoptysis (blood in sputum), and pain\\] and 3 global items (symptom distress, interference with activity level, and global quality of life). Participant responses to each item were measured using visual analogue scales (VAS) with 100-millimeter (mm) lines. A higher score for any item represented a higher level of symptoms/problems. The LCSS total score was defined as the mean of all 9 items. Average symptom burden index (ASBI) was calculated as the mean of the six symptom-specific questions from the LCSS. Potential scores range from 0 (for best outcome) to 100 (for worst outcome).","populationDescription":"Part B: All randomized participants who completed the LCSS at baseline and at least once post-baseline. Per protocol, Part A did not evaluate efficacy.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"millimeter","timeFrame":"Baseline, End of Study (Up To 37 Months)","groups":[{"id":"OG000","title":"Part B: Ramucirumab+ Erlotinib","description":"Part B: 10 mg/kg ramucirumab administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG001","title":"Part B: Placebo+ Erlotinib","description":"Part B: Placebo administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"225"}]}],"classes":[{"title":"Loss of Appetite","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"213"},{"groupId":"OG001","value":"217"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-17.07","spread":"0.92"},{"groupId":"OG001","value":"-18.16","spread":"0.91"}]}]},{"title":"Fatigue","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"213"},{"groupId":"OG001","value":"217"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-19.35","spread":"0.91"},{"groupId":"OG001","value":"-19.45","spread":"0.90"}]}]},{"title":"Cough","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"213"},{"groupId":"OG001","value":"217"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-21.22","spread":"0.58"},{"groupId":"OG001","value":"-22.09","spread":"0.57"}]}]},{"title":"Shortness of Breath","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"213"},{"groupId":"OG001","value":"217"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-14.46","spread":"0.57"},{"groupId":"OG001","value":"-15.93","spread":"0.57"}]}]},{"title":"Blood in Sputum","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"213"},{"groupId":"OG001","value":"216"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.58","spread":"0.25"},{"groupId":"OG001","value":"-1.94","spread":"0.25"}]}]},{"title":"Pain","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"213"},{"groupId":"OG001","value":"216"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-13.57","spread":"0.59"},{"groupId":"OG001","value":"-14.69","spread":"0.59"}]}]},{"title":"Symptom distress","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"213"},{"groupId":"OG001","value":"217"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-15.91","spread":"0.67"},{"groupId":"OG001","value":"-16.15","spread":"0.67"}]}]},{"title":"Interference with Activity Level","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"213"},{"groupId":"OG001","value":"217"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-14.43","spread":"0.83"},{"groupId":"OG001","value":"-15.60","spread":"0.82"}]}]},{"title":"Global Quality of Life","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"213"},{"groupId":"OG001","value":"217"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-16.21","spread":"0.95"},{"groupId":"OG001","value":"-18.12","spread":"0.94"}]}]},{"title":"Average Symptom Burden Index","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"213"},{"groupId":"OG001","value":"216"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-12.17","spread":"0.57"},{"groupId":"OG001","value":"-13.05","spread":"0.57"}]}]},{"title":"Total LCSS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"213"},{"groupId":"OG001","value":"216"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-12.00","spread":"0.62"},{"groupId":"OG001","value":"-12.71","spread":"0.61"}]}]}]},{"type":"SECONDARY","title":"Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score","description":"The EQ-5D-5L is a standardized instrument used to measure self-reported health status of the participants. It consists of 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). There are 5 response levels (no problems, slight problems, moderate problems, severe problems, and extreme problems/unable to), ranging from 1 to 5 (good to bad). Dimension responses were converted to an index score using UK weights. The index scores were anchored on full health (1.0) to dead (0) with negative values assigned to health states considered worse than death.","populationDescription":"Part B: All randomized participants who completed the EQ-5D-5L at baseline and at least once post-baseline. Per protocol, Part A did not evaluate efficacy.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Baseline, Cycle 10 (each cycle is 2 weeks)","groups":[{"id":"OG000","title":"Part B: Ramucirumab+ Erlotinib","description":"Part B: 10 mg/kg ramucirumab every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG001","title":"Part B: Placebo+ Erlotinib","description":"Part B: Placebo every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"170"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.15"},{"groupId":"OG001","value":"0.02","spread":"0.15"}]}]}]},{"type":"SECONDARY","title":"Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score","description":"The EQ-5D-5L is a standardized instrument used to measure self-reported health status of the participants. It consists of 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). There are 5 response levels (no problems, slight problems, moderate problems, severe problems, and extreme problems/unable to), ranging from 1 to 5 (good to bad). Dimension responses were converted to an index score using UK weights. The index scores were anchored on full health (1.0) to dead (0) with negative values assigned to health states considered worse than death.","populationDescription":"Part B: All randomized participants who completed the EQ-5D-5L at baseline and at least once post-baseline. Per protocol, Part A did not evaluate efficacy.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Baseline, Cycle 28 (each cycle is 2 weeks)","groups":[{"id":"OG000","title":"Part B: Ramucirumab+ Erlotinib","description":"Part B: 10 mg/kg ramucirumab every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG001","title":"Part B: Placebo+ Erlotinib","description":"Part B: Placebo every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"81"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.18"},{"groupId":"OG001","value":"0.01","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Part B: Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score","description":"The EQ-5D-5L is a standardized instrument used to measure self-reported health status of the participants. It consists of 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). There are 5 response levels (no problems, slight problems, moderate problems, severe problems, and extreme problems/unable to), ranging from 1 to 5 (good to bad). Dimension responses were converted to an index score using UK weights. The index scores were anchored on full health (1.0) to dead (0) with negative values assigned to health states considered worse than death.","populationDescription":"Part B: All randomized participants who completed the EQ-5D-5L at baseline and at least once post-baseline. Per protocol, Part A did not evaluate efficacy.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Baseline, Cycle 40 (each cycle is 2 weeks)","groups":[{"id":"OG000","title":"Part B: Ramucirumab+ Erlotinib","description":"Part B: 10 mg/kg ramucirumab every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG001","title":"Part B: Placebo+ Erlotinib","description":"Part B: Placebo every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"44"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.15"},{"groupId":"OG001","value":"-0.01","spread":"0.14"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up To 3 Years","description":"Serious Adverse Events and Other Adverse Events: All participants who received at least one dose of study drug; All-Cause Mortality: All randomized participants. Part C data will be reported after study completion. Gender specific events only occurring in male or female participants have had the number of participants at risk adjusted accordingly.","eventGroups":[{"id":"EG000","title":"Part A: Ramucirumab + Erlotinib","description":"Part A: 10 milligrams per kilogram (mg/kg) ramucirumab administered every 2 weeks intravenously (IV) in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met.","deathsNumAffected":2,"deathsNumAtRisk":14,"seriousNumAffected":0,"seriousNumAtRisk":14,"otherNumAffected":14,"otherNumAtRisk":14},{"id":"EG001","title":"Part B: Ramucirumab + Erlotinib","description":"Part B: 10 mg/kg ramucirumab administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met.","deathsNumAffected":37,"deathsNumAtRisk":224,"seriousNumAffected":65,"seriousNumAtRisk":221,"otherNumAffected":220,"otherNumAtRisk":221},{"id":"EG002","title":"Part B: Placebo + Erlotinib","description":"Part B: Placebo administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met.","deathsNumAffected":42,"deathsNumAtRisk":225,"seriousNumAffected":47,"seriousNumAtRisk":225,"otherNumAffected":225,"otherNumAtRisk":225}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Wolff-parkinson-white syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":225}]},{"term":"Macular fibrosis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Retinal detachment","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":4,"numAffected":1,"numAtRisk":225}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Colitis ischaemic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Duodenal ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Irritable bowel syndrome","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Lower gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Melaena","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":225}]},{"term":"Small intestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":221},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":225}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Mucous membrane disorder","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":221},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":225}]},{"term":"Drug-induced liver injury","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":225}]},{"term":"Hepatic function abnormal","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":5,"numAffected":3,"numAtRisk":221},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":225}]},{"term":"Hepatic steatosis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Liver disorder","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Abdominal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Appendicitis perforated","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Empyema","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Encephalitis influenzal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Gastroenteritis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Infectious pleural effusion","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":225}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Meningitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Rash pustular","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Concussion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Humerus fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Radius fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Rib fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Ulna fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":221},{"groupId":"EG002","numEvents":3,"numAffected":1,"numAtRisk":225}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":225}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":8,"numAffected":3,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":225}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Adenocarcinoma of colon","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Basal cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Cancer pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Lymphoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Mesenteric neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Ovarian neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":139},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":142}]},{"term":"Pericarditis malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Depressed level of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":225}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Hydrocephalus","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Neuralgia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Adjustment disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Endometriosis","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":139},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":142}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Haemothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":225}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Pleurisy","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Pneumomediastinum","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":221},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":225}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":221},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":225}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Dermatitis exfoliative generalised","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Eczema asteatotic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Skin exfoliation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Hepatectomy","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":49,"numAffected":21,"numAtRisk":221},{"groupId":"EG002","numEvents":15,"numAffected":10,"numAtRisk":225}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":14},{"groupId":"EG001","numEvents":9,"numAffected":3,"numAtRisk":221},{"groupId":"EG002","numEvents":11,"numAffected":2,"numAtRisk":225}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":9,"numAffected":5,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Sinus bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":16,"numAffected":12,"numAtRisk":221},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":225}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Blepharitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":7,"numAffected":4,"numAtRisk":221},{"groupId":"EG002","numEvents":11,"numAffected":9,"numAtRisk":225}]},{"term":"Dry eye","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":27,"numAffected":22,"numAtRisk":221},{"groupId":"EG002","numEvents":24,"numAffected":23,"numAtRisk":225}]},{"term":"Eyelid oedema","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Ocular discomfort","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Ocular hyperaemia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":221},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":225}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":225}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":14},{"groupId":"EG001","numEvents":26,"numAffected":15,"numAtRisk":221},{"groupId":"EG002","numEvents":18,"numAffected":15,"numAtRisk":225}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":14},{"groupId":"EG001","numEvents":23,"numAffected":17,"numAtRisk":221},{"groupId":"EG002","numEvents":41,"numAffected":19,"numAtRisk":225}]},{"term":"Anal fissure","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":5,"numAffected":2,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Anal fistula","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Cheilitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":221},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":225}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":14},{"groupId":"EG001","numEvents":52,"numAffected":42,"numAtRisk":221},{"groupId":"EG002","numEvents":38,"numAffected":31,"numAtRisk":225}]},{"term":"Dental caries","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":221},{"groupId":"EG002","numEvents":8,"numAffected":8,"numAtRisk":225}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":57,"numAffected":13,"numAtRisk":14},{"groupId":"EG001","numEvents":410,"numAffected":154,"numAtRisk":221},{"groupId":"EG002","numEvents":388,"numAffected":160,"numAtRisk":225}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":221},{"groupId":"EG002","numEvents":5,"numAffected":3,"numAtRisk":225}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":17,"numAffected":11,"numAtRisk":221},{"groupId":"EG002","numEvents":21,"numAffected":12,"numAtRisk":225}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":221},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":225}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":22,"numAffected":19,"numAtRisk":221},{"groupId":"EG002","numEvents":11,"numAffected":9,"numAtRisk":225}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":22,"numAffected":16,"numAtRisk":221},{"groupId":"EG002","numEvents":12,"numAffected":9,"numAtRisk":225}]},{"term":"Gingival bleeding","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":14},{"groupId":"EG001","numEvents":23,"numAffected":19,"numAtRisk":221},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":225}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":19,"numAffected":14,"numAtRisk":221},{"groupId":"EG002","numEvents":12,"numAffected":9,"numAtRisk":225}]},{"term":"Inguinal hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":14},{"groupId":"EG001","numEvents":81,"numAffected":57,"numAtRisk":221},{"groupId":"EG002","numEvents":79,"numAffected":44,"numAtRisk":225}]},{"term":"Oesophageal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Rectal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":14},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":6,"numAtRisk":14},{"groupId":"EG001","numEvents":148,"numAffected":92,"numAtRisk":221},{"groupId":"EG002","numEvents":144,"numAffected":82,"numAtRisk":225}]},{"term":"Tooth disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":14},{"groupId":"EG001","numEvents":34,"numAffected":26,"numAtRisk":221},{"groupId":"EG002","numEvents":31,"numAffected":25,"numAtRisk":225}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":3,"numAtRisk":14},{"groupId":"EG001","numEvents":34,"numAffected":17,"numAtRisk":221},{"groupId":"EG002","numEvents":29,"numAffected":14,"numAtRisk":225}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":14},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":221},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":225}]},{"term":"Cyst","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":2,"numAtRisk":14},{"groupId":"EG001","numEvents":55,"numAffected":25,"numAtRisk":221},{"groupId":"EG002","numEvents":51,"numAffected":27,"numAtRisk":225}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":8,"numAffected":5,"numAtRisk":221},{"groupId":"EG002","numEvents":17,"numAffected":13,"numAtRisk":225}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":69,"numAffected":34,"numAtRisk":221},{"groupId":"EG002","numEvents":35,"numAffected":19,"numAtRisk":225}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":14},{"groupId":"EG001","numEvents":28,"numAffected":14,"numAtRisk":221},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":225}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":13,"numAffected":10,"numAtRisk":221},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":225}]},{"term":"Oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":14},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":221},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":225}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":14},{"groupId":"EG001","numEvents":78,"numAffected":50,"numAtRisk":221},{"groupId":"EG002","numEvents":11,"numAffected":10,"numAtRisk":225}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":221},{"groupId":"EG002","numEvents":10,"numAffected":9,"numAtRisk":225}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":14},{"groupId":"EG001","numEvents":57,"numAffected":45,"numAtRisk":221},{"groupId":"EG002","numEvents":34,"numAffected":24,"numAtRisk":225}]},{"term":"Xerosis","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":221},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":225}]},{"term":"Hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":6,"numAffected":2,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Allergy to arthropod sting","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":225}]},{"term":"Angular cheilitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":221},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":225}]},{"term":"Bacteriuria","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Candida infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":2,"numAtRisk":14},{"groupId":"EG001","numEvents":26,"numAffected":21,"numAtRisk":221},{"groupId":"EG002","numEvents":40,"numAffected":32,"numAtRisk":225}]},{"term":"Cystitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":12,"numAffected":8,"numAtRisk":221},{"groupId":"EG002","numEvents":17,"numAffected":9,"numAtRisk":225}]},{"term":"Eye infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Folliculitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":17,"numAffected":7,"numAtRisk":221},{"groupId":"EG002","numEvents":15,"numAffected":11,"numAtRisk":225}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":221},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":225}]},{"term":"Gingivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":16,"numAffected":6,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":14},{"groupId":"EG001","numEvents":27,"numAffected":22,"numAtRisk":221},{"groupId":"EG002","numEvents":28,"numAffected":18,"numAtRisk":225}]},{"term":"Paronychia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":10,"numAtRisk":14},{"groupId":"EG001","numEvents":277,"numAffected":118,"numAtRisk":221},{"groupId":"EG002","numEvents":238,"numAffected":114,"numAtRisk":225}]},{"term":"Parotitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Perichondritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":20,"numAffected":15,"numAtRisk":221},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":225}]},{"term":"Pulpitis dental","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Rash pustular","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":12,"numAffected":6,"numAtRisk":221},{"groupId":"EG002","numEvents":34,"numAffected":14,"numAtRisk":225}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":221},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":225}]},{"term":"Tinea cruris","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":2,"numAtRisk":14},{"groupId":"EG001","numEvents":53,"numAffected":38,"numAtRisk":221},{"groupId":"EG002","numEvents":52,"numAffected":34,"numAtRisk":225}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":14},{"groupId":"EG001","numEvents":23,"numAffected":17,"numAtRisk":221},{"groupId":"EG002","numEvents":21,"numAffected":11,"numAtRisk":225}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":221},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":225}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":221},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":225}]},{"term":"Skin abrasion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Skin laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":225}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":7,"numAtRisk":14},{"groupId":"EG001","numEvents":270,"numAffected":93,"numAtRisk":221},{"groupId":"EG002","numEvents":192,"numAffected":70,"numAtRisk":225}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":14},{"groupId":"EG001","numEvents":270,"numAffected":92,"numAtRisk":221},{"groupId":"EG002","numEvents":128,"numAffected":58,"numAtRisk":225}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":14},{"groupId":"EG001","numEvents":39,"numAffected":23,"numAtRisk":221},{"groupId":"EG002","numEvents":46,"numAffected":20,"numAtRisk":225}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":14},{"groupId":"EG001","numEvents":254,"numAffected":68,"numAtRisk":221},{"groupId":"EG002","numEvents":251,"numAffected":70,"numAtRisk":225}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":13,"numAffected":5,"numAtRisk":221},{"groupId":"EG002","numEvents":8,"numAffected":6,"numAtRisk":225}]},{"term":"Blood lactate dehydrogenase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":22,"numAffected":6,"numAtRisk":221},{"groupId":"EG002","numEvents":11,"numAffected":2,"numAtRisk":225}]},{"term":"Electrocardiogram qt prolonged","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":6,"numAffected":3,"numAtRisk":221},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":225}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":35,"numAffected":12,"numAtRisk":221},{"groupId":"EG002","numEvents":11,"numAffected":7,"numAtRisk":225}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":83,"numAffected":25,"numAtRisk":221},{"groupId":"EG002","numEvents":39,"numAffected":16,"numAtRisk":225}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":14},{"groupId":"EG001","numEvents":54,"numAffected":31,"numAtRisk":221},{"groupId":"EG002","numEvents":10,"numAffected":6,"numAtRisk":225}]},{"term":"Transaminases increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":5,"numAffected":2,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":54,"numAffected":28,"numAtRisk":221},{"groupId":"EG002","numEvents":37,"numAffected":29,"numAtRisk":225}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":53,"numAffected":14,"numAtRisk":221},{"groupId":"EG002","numEvents":14,"numAffected":7,"numAtRisk":225}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":4,"numAtRisk":14},{"groupId":"EG001","numEvents":101,"numAffected":57,"numAtRisk":221},{"groupId":"EG002","numEvents":84,"numAffected":47,"numAtRisk":225}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":27,"numAffected":14,"numAtRisk":221},{"groupId":"EG002","numEvents":17,"numAffected":10,"numAtRisk":225}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":38,"numAffected":18,"numAtRisk":221},{"groupId":"EG002","numEvents":12,"numAffected":5,"numAtRisk":225}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":4,"numAffected":2,"numAtRisk":225}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":14},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":221},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":225}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":14},{"groupId":"EG001","numEvents":28,"numAffected":24,"numAtRisk":221},{"groupId":"EG002","numEvents":22,"numAffected":17,"numAtRisk":225}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":12,"numAffected":9,"numAtRisk":221},{"groupId":"EG002","numEvents":11,"numAffected":8,"numAtRisk":225}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":221},{"groupId":"EG002","numEvents":15,"numAffected":12,"numAtRisk":225}]},{"term":"Musculoskeletal discomfort","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":14},{"groupId":"EG001","numEvents":14,"numAffected":12,"numAtRisk":221},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":225}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":10,"numAffected":5,"numAtRisk":221},{"groupId":"EG002","numEvents":9,"numAffected":9,"numAtRisk":225}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":14},{"groupId":"EG001","numEvents":8,"numAffected":6,"numAtRisk":221},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":225}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":14},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":221},{"groupId":"EG002","numEvents":16,"numAffected":12,"numAtRisk":225}]},{"term":"Tendonitis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Cancer pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":225}]},{"term":"Pyogenic granuloma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":14},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":27,"numAffected":20,"numAtRisk":221},{"groupId":"EG002","numEvents":24,"numAffected":19,"numAtRisk":225}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":14},{"groupId":"EG001","numEvents":46,"numAffected":39,"numAtRisk":221},{"groupId":"EG002","numEvents":44,"numAffected":32,"numAtRisk":225}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":7,"numAtRisk":14},{"groupId":"EG001","numEvents":56,"numAffected":33,"numAtRisk":221},{"groupId":"EG002","numEvents":21,"numAffected":16,"numAtRisk":225}]},{"term":"Neuralgia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":225}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":221},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":225}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":221},{"groupId":"EG002","numEvents":10,"numAffected":9,"numAtRisk":225}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":16,"numAffected":7,"numAtRisk":221},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":225}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Depressed mood","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":221},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":225}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":14},{"groupId":"EG001","numEvents":36,"numAffected":32,"numAtRisk":221},{"groupId":"EG002","numEvents":33,"numAffected":29,"numAtRisk":225}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":11,"numAffected":10,"numAtRisk":221},{"groupId":"EG002","numEvents":12,"numAffected":8,"numAtRisk":225}]},{"term":"Leukocyturia","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":5,"numAtRisk":14},{"groupId":"EG001","numEvents":278,"numAffected":75,"numAtRisk":221},{"groupId":"EG002","numEvents":35,"numAffected":19,"numAtRisk":225}]},{"term":"Genital rash","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":3,"numAtRisk":14},{"groupId":"EG001","numEvents":62,"numAffected":48,"numAtRisk":221},{"groupId":"EG002","numEvents":49,"numAffected":35,"numAtRisk":225}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":14},{"groupId":"EG001","numEvents":17,"numAffected":14,"numAtRisk":221},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":225}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":14},{"groupId":"EG001","numEvents":25,"numAffected":18,"numAtRisk":221},{"groupId":"EG002","numEvents":9,"numAffected":9,"numAtRisk":225}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":14},{"groupId":"EG001","numEvents":102,"numAffected":74,"numAtRisk":221},{"groupId":"EG002","numEvents":33,"numAffected":27,"numAtRisk":225}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":14},{"groupId":"EG001","numEvents":19,"numAffected":11,"numAtRisk":221},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":225}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":225}]},{"term":"Nasal disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Nasal inflammation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":14},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":221},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":225}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":25,"numAffected":19,"numAtRisk":221},{"groupId":"EG002","numEvents":14,"numAffected":13,"numAtRisk":225}]},{"term":"Orthopnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG001","numEvents":21,"numAffected":15,"numAtRisk":221},{"groupId":"EG002","numEvents":17,"numAffected":11,"numAtRisk":225}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":17,"numAffected":13,"numAtRisk":221},{"groupId":"EG002","numEvents":9,"numAffected":9,"numAtRisk":225}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":14},{"groupId":"EG001","numEvents":84,"numAffected":75,"numAtRisk":221},{"groupId":"EG002","numEvents":47,"numAffected":44,"numAtRisk":225}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":33,"numAffected":9,"numAtRisk":14},{"groupId":"EG001","numEvents":433,"numAffected":149,"numAtRisk":221},{"groupId":"EG002","numEvents":447,"numAffected":153,"numAtRisk":225}]},{"term":"Dermatitis contact","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":221},{"groupId":"EG002","numEvents":10,"numAffected":6,"numAtRisk":225}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":9,"numAtRisk":14},{"groupId":"EG001","numEvents":127,"numAffected":83,"numAtRisk":221},{"groupId":"EG002","numEvents":181,"numAffected":91,"numAtRisk":225}]},{"term":"Ecchymosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":83,"numAffected":12,"numAtRisk":221},{"groupId":"EG002","numEvents":24,"numAffected":10,"numAtRisk":225}]},{"term":"Hair disorder","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Hirsutism","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":139},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":142}]},{"term":"Intertrigo","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Nail dystrophy","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":225}]},{"term":"Nail toxicity","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":225}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":5,"numAtRisk":14},{"groupId":"EG001","numEvents":110,"numAffected":51,"numAtRisk":221},{"groupId":"EG002","numEvents":165,"numAffected":66,"numAtRisk":225}]},{"term":"Purpura","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":14},{"groupId":"EG001","numEvents":17,"numAffected":11,"numAtRisk":221},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":225}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":5,"numAtRisk":14},{"groupId":"EG001","numEvents":103,"numAffected":39,"numAtRisk":221},{"groupId":"EG002","numEvents":148,"numAffected":54,"numAtRisk":225}]},{"term":"Rash macular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":4,"numAtRisk":14},{"groupId":"EG001","numEvents":47,"numAffected":20,"numAtRisk":221},{"groupId":"EG002","numEvents":53,"numAffected":21,"numAtRisk":225}]},{"term":"Skin fissures","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":14},{"groupId":"EG001","numEvents":13,"numAffected":9,"numAtRisk":221},{"groupId":"EG002","numEvents":19,"numAffected":14,"numAtRisk":225}]},{"term":"Skin lesion","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":4,"numAffected":2,"numAtRisk":221},{"groupId":"EG002","numEvents":4,"numAffected":2,"numAtRisk":225}]},{"term":"Xeroderma","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":225}]},{"term":"Dental care","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Dental operation","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Inguinal hernia repair","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Tooth extraction","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":221},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":225}]},{"term":"Vaginal pessary insertion","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":139},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":142}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":7,"numAtRisk":14},{"groupId":"EG001","numEvents":246,"numAffected":100,"numAtRisk":221},{"groupId":"EG002","numEvents":72,"numAffected":27,"numAtRisk":225}]},{"term":"Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]},{"term":"Varicose ulceration","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":221},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":225}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","email":"ClinicalTrials.gov@lilly.com","phone":"800-545-5979"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol: Protocol I4T-MC-JVCY(f)","date":"2018-04-23","uploadDate":"2020-01-14T17:44","filename":"Prot_000.pdf","size":9569454},{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol: Protocol Addendum I4T-MC-JVCY(9)","date":"2017-08-15","uploadDate":"2020-01-14T17:49","filename":"Prot_002.pdf","size":818838},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2018-12-13","uploadDate":"2020-01-14T17:46","filename":"SAP_001.pdf","size":662728}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000096662","term":"Ramucirumab"},{"id":"D000069347","term":"Erlotinib Hydrochloride"},{"id":"D000077156","term":"Gefitinib"},{"id":"C000596361","term":"osimertinib"}],"ancestors":[{"id":"D061067","term":"Antibodies, Monoclonal, Humanized"},{"id":"D000911","term":"Antibodies, Monoclonal"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"},{"id":"D011799","term":"Quinazolines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"}]}},"hasResults":true}